

Osteoarthritis Market - A Global and Regional Analysis: Focus on Drug Type, Route of Administration, Site, and Region - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/O3B5B98089A9EN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: O3B5B98089A9EN

Abstracts

The global osteoarthritis market is witnessing significant expansion driven by the rising prevalence of degenerative joint diseases, increasing geriatric population, and growing awareness of advanced treatment modalities. Osteoarthritis, a chronic joint disorder marked by the progressive breakdown of cartilage, affects millions globally, particularly in aging populations across the U.S., Europe, and Asia-Pacific. The burden of osteoarthritis continues to increase due to sedentary lifestyles, obesity, and longer life expectancy, reinforcing the need for effective and sustained therapeutic solutions.

Growth in the osteoarthritis market is supported by advancements in pharmacological therapies, regenerative medicine, and surgical interventions aimed at improving joint function and reducing pain. The market is undergoing transformation as pharmaceutical and biotechnology companies focus on novel formulations, extended-release drug delivery systems, and disease-modifying osteoarthritis drugs (DMOADs). Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and viscosupplementation agents remain standard treatment options; however, innovations in biologics and intra-articular injections are driving the next phase of growth within the osteoarthritis market.

Technological progress in imaging, diagnostics, and 3D joint modeling further aids early detection and personalized treatment approaches, strengthening patient outcomes. The growing adoption of minimally invasive surgical procedures and regenerative therapies using stem cells and platelet-rich plasma (PRP) has broadened therapeutic scope, especially in developed markets such as the U.S., U.K., Germany, and Japan. Increasing reimbursement support and policy reforms promoting musculoskeletal health

also enhance the accessibility of care, fuelling the expansion of the osteoarthritis market.

Despite promising advancements, the osteoarthritis market faces certain challenges. The high cost of biologics, limited curative therapies, and variable patient responses to pharmacologic agents hinder uniform market penetration. Additionally, the chronic and progressive nature of osteoarthritis complicates long-term disease management, necessitating continuous innovation in pain management and cartilage regeneration techniques. Regulatory barriers and lengthy clinical approval processes further delay the introduction of next-generation products.

The competitive landscape of the osteoarthritis market is marked by active participation from leading players, including Pfizer Inc., GlaxoSmithKline plc, Bayer AG, Novartis AG, and Zimmer Biomet. These companies are engaged in strategic collaborations, mergers, and acquisitions to enhance product portfolios and strengthen R&D capabilities. Start-ups and mid-sized firms specializing in regenerative and cell-based therapies are also entering the space, driving product differentiation and clinical innovation.

Looking ahead, the global osteoarthritis market is poised for sustained growth as new biologics, gene therapies, and combination treatments gain regulatory approval. The integration of digital health tools for remote patient monitoring and patient adherence, combined with AI-driven diagnostics and outcome tracking, is expected to redefine disease management. As healthcare systems increasingly emphasize cost-effective, patient-centric care, the osteoarthritis market is projected to deliver improved quality of life and mobility for millions affected worldwide.

Market Segmentation:

Segmentation 1: by Drug Type

Analgesics

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Corticosteroids

Viscosupplementation Agents

Others

Segmentation 2: by Route of Administration

Topical

Oral

Parenteral

Segmentation 3: by Site

Hands

Knee

Hips

Others

Segmentation 4: by Region

North America

Europe

Asia-Pacific

Rest-of-the-World

The osteoarthritis market will continue to evolve with a focus on targeted biologics, regenerative therapies, and advanced pain management solutions. Expanding healthcare infrastructure, favorable reimbursement frameworks, and ongoing research in DMOADs will play a crucial role in shaping the osteoarthritis market's long-term trajectory.

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. GLOBAL OSTEOARTHRITIS MARKET: INDUSTRY ANALYSIS

1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
 1.3.1 Impact Analysis
1.4 Patent Analysis
 1.4.1 Patent Filing Trend (by Country)
 1.4.2 Patent Filing Trend (by Year)
1.5 Regulatory Landscape
1.6 Ongoing Clinical Trials
1.7 Market Dynamics
 1.7.1 Overview
 1.7.2 Market Drivers
 1.7.3 Market Restraints
 1.7.4 Market Opportunities

2. GLOBAL OSTEOARTHRITIS MARKET, BY DRUG TYPE, \$MILLION, 2024-2035

2.1 Analgesics
2.2 Non-Steroidal Anti-inflammatory drugs
2.3 Corticosteroids
2.4 Viscosupplementation agents
2.5 Other

3. GLOBAL OSTEOARTHRITIS MARKET, BY ROUTE OF ADMINISTRATION, \$MILLION, 2024-2035

3.1 Topical
3.2 Oral

3.3 Parenteral/Intravenous

4. GLOBAL OSTEOARTHRITIS MARKET, BY SITE, \$MILLION, 2024-2035

4.1 Hands

4.2 Knee

4.3 Hips

4.4 Others

5. GLOBAL OSTEOARTHRITIS MARKET, BY REGION, \$MILLION, 2024-2035

5.1 North America

5.1.1 Market Dynamics

5.1.2 Market Sizing and Forecast

5.1.3 North America Osteoarthritis Market, by Country

5.1.3.1 U.S.

5.2 Europe

5.2.1 Market Dynamics

5.2.2 Market Sizing and Forecast

5.2.3 Europe Osteoarthritis Market, by Country

5.2.3.1 U.K.

5.2.3.2 France

5.2.3.3 Germany

5.2.3.4 Italy

5.2.3.5 Spain

5.3 Asia-Pacific

5.3.1 Market Dynamics

5.3.2 Market Sizing and Forecast

5.3.3 Asia-Pacific Osteoarthritis Market, by Country

5.3.3.1 Japan

5.3.3.2 China

5.3.3.3 South Korea

5.3.3.4 Australia

5.3.3.5 India

5.4 Rest-of-the-World

5.4.1 Market Dynamics

5.4.2 Market Sizing and Forecast

6. GLOBAL OSTEOARTHRITIS MARKET, COMPETITIVE LANDSCAPE AND

COMPANY PROFILES

6.1 Competitive Landscape

6.1.1 Mergers and Acquisitions

6.1.2 Partnership, Alliances and Business Expansion

6.1.3 New Offerings

6.1.4 Regulatory Activities

6.1.5 Funding Activities

6.2 Company Profiles

6.2.1 Kenvue

6.2.1.1 Overview

6.2.1.2 Top Products / Product Portfolio

6.2.1.3 Top Competitors

6.2.1.4 Target Customers/End-Users

6.2.1.5 Key Personnel

6.2.1.6 Analyst View

6.2.2 GlaxoSmithKline plc

6.2.2.1 Overview

6.2.2.2 Top Products / Product Portfolio

6.2.2.3 Top Competitors

6.2.2.4 Target Customers/End-Users

6.2.2.5 Key Personnel

6.2.2.6 Analyst View

6.2.3 Pfizer Inc.

6.2.3.1 Overview

6.2.3.2 Top Products / Product Portfolio

6.2.3.3 Top Competitors

6.2.3.4 Target Customers/End-Users

6.2.3.5 Key Personnel

6.2.3.6 Analyst View

6.2.4 Bayer AG

6.2.4.1 Overview

6.2.4.2 Top Products / Product Portfolio

6.2.4.3 Top Competitors

6.2.4.4 Target Customers/End-Users

6.2.4.5 Key Personnel

6.2.4.6 Analyst View

6.2.5 Zimmer Biomet

6.2.5.1 Overview

- 6.2.5.2 Top Products / Product Portfolio
- 6.2.5.3 Top Competitors
- 6.2.5.4 Target Customers/End-Users
- 6.2.5.5 Key Personnel
- 6.2.5.6 Analyst View
- 6.2.6 Novartis AG
 - 6.2.6.1 Overview
 - 6.2.6.2 Top Products / Product Portfolio
 - 6.2.6.3 Top Competitors
 - 6.2.6.4 Target Customers/End-Users
 - 6.2.6.5 Key Personnel
 - 6.2.6.6 Analyst View
- 6.2.7 Anika Therapeutics, Inc.
 - 6.2.7.1 Overview
 - 6.2.7.2 Top Products / Product Portfolio
 - 6.2.7.3 Top Competitors
 - 6.2.7.4 Target Customers/End-Users
 - 6.2.7.5 Key Personnel
 - 6.2.7.6 Analyst View
- 6.2.8 Bioventus LLC
 - 6.2.8.1 Overview
 - 6.2.8.2 Top Products / Product Portfolio
 - 6.2.8.3 Top Competitors
 - 6.2.8.4 Target Customers/End-Users
 - 6.2.8.5 Key Personnel
 - 6.2.8.6 Analyst View
- 6.2.9 Ferring Pharmaceuticals
 - 6.2.9.1 Overview
 - 6.2.9.2 Top Products / Product Portfolio
 - 6.2.9.3 Top Competitors
 - 6.2.9.4 Target Customers/End-Users
 - 6.2.9.5 Key Personnel
 - 6.2.9.6 Analyst View

7. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Osteoarthritis Market (by Scenario), \$Million, 2024, 2030, and 2035

Figure: Global Osteoarthritis Market, 2024 and 2035

Figure: Global Osteoarthritis Market Key Trends, Impact Analysis

Figure: North America Osteoarthritis Market, \$Million, 2024-2035

Figure: Europe Osteoarthritis Market, \$Million, 2024-2035

Figure: Asia-Pacific Osteoarthritis Market, \$Million, 2024-2035

Figure: Rest-of-the-World Osteoarthritis Market, \$Million, 2024-2035

List Of Tables

LIST OF TABLES

Table: Market Snapshot

Table: Market Dynamics

Table: Global Osteoarthritis Market (by Drug Type), \$Million, 2024-2035

Table: Global Osteoarthritis Market (by Route of Administration), \$Million, 2024-2035

Table: Global Osteoarthritis Market (by Site), \$Million, 2024-2035

Table: Global Osteoarthritis Market (by Region), \$Million, 2024-2035

I would like to order

Product name: Osteoarthritis Market - A Global and Regional Analysis: Focus on Drug Type, Route of Administration, Site, and Region - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/O3B5B98089A9EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O3B5B98089A9EN.html>